From: Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Receptor | LAG-3 | TIM-3 | TIGIT | VISTA | B7-H3 | BTLA |
---|---|---|---|---|---|---|
Alternate name | CD223 | HAVCR2 | WUCAM/ Vstm3/ Vsig9 | PD-1H/DD1α/ Gi24/Dies1/B7-H5 | CD276 | CD272 |
Chromosomal location | 12p13.32 | 5q33.2 | 3q13.31 | 10q22.1 | 15q24.1 | 3q13.2 |
Function of ligand-receptor interaction | Co-inhibition | Co-inhibition | Co-inhibition | Co-inhibition | Co-inhibition or co-stimulation | Co-inhibition |
Binding Partner | MHC-II, galectin-3, LSECtin, a-synuclein, FGL1 | Galectin-9, Ceacam-1, HMGB-1, PtdSer | CD155, CD112 | VSIG-3 | Unknow | HVEM |
Number of amino acids | 498 amino acids | 302 amino acids | 244Â amino acids | 311 amino acids | 316 amino acids | 289 amino acids |
Signaling motif | KIEELE motif | Tyrosine residues | ITT and ITIM | Unknow | Unknow | ITIM and ITSM |
Receptor Expression | Activated T cells, B cells, Tregs, NK cells, DCs | Activated T cells, B cells, Tregs, DCs, NK cells, monocytes | T cells, NK cells | Myeloid cells, T cells | Activated T cells, NK cells, DCs, monocytes, tumor tissue | Mature B cells, T cells, Tregs, macrophages, DCs |